Table 1.
Demographic and serological findings from 522 subjects and 614 serum samples tested for MOG-IgG
| Diagnostic categories | Sample numbers | Patient numbers | Sex ratio (m:f) | Age (ys), median | MOG-IgG+, samples | MOG-IgG+, patients | MOG-IgG+, median§ | AQP4-IgG +, MOG-IgG + patients |
|---|---|---|---|---|---|---|---|---|
| Group I | 386 | 300 | 1:2.4 | 39 | 95/386 (24.6 %) | 50/300 (16.7 %) | 1:640 | 0/50 (0 %) |
| “ON and/or MY”a | 281 | 202 | 95/281 (33.8 %) | 50/202 (24.8 %) | 1:640 | 0/50 (0 %) | ||
| “ON and MY”a | 79 | 54 | 39/79 (49.4 %) | 22/54 (40.7 %) | 1:1280 | 0/22 (0 %) | ||
| “mON/rON”a | 145 | 103 | 47/145 (32.4 %) | 22/103 (21.4 %) | 1:640 | 0/22 (0 %) | ||
| “mON”a | 69 | 66 | 10/69 (14.5 %) | 9/66 (13.6 %) | 1:800 | 0/9 (0 %) | ||
| “rON”a | 76 | 37 | 37/76 (48.7 %) | 13/37 (35.1 %) | 1:640 | 0/13 (0 %) | ||
| “MY” (all LETM)a | 57 | 45 | 9/57 (15.8 %) | 6/45 (13.3 %) | 1:2560 | 0/6 (0 %) | ||
| “MS”a | 58 | 54 | 0/58 (0 %) | 0/54 (0 %) | N.a. | N.a. | ||
| “OND”a | 47 | 44 | 0/47 (0 %) | 0/44 (0 %) | N.a. | N.a. | ||
| Group II | 89 | 83 | 1:1.9 | 46 | 0/89 (0 %) | 0/83 (0 %) | N.a. | 89/89 (100 %) |
| AQP4+ NMO | 59 | 56 | 0/59 (0 %) | 0/56 (0 %) | N.a. | 59/59 (100 %) | ||
| AQP4+ rON | 5 | 5 | 0/25 (0 %) | 0/22 (0 %) | N.a. | 25/25 (100 %) | ||
| AQP4+ LETM | 25 | 22 | 0/5 (0 %) | 0/5 (0 %) | N.a. | 5/5 (100 %) | ||
| Group III | 85 | 85 | 1:3 | 38 | 0/85 (0 %) | 0/85 (0 %) | N.a. | N.a. |
| RRMS | 73 | 73 | 0/73 (0 %) | 0/73 (0 %) | N.a. | N.a. | ||
| SPMS | 9 | 9 | 0/9 (0 %) | 0/9 (0 %) | N.a. | N.a. | ||
| PPMS | 3 | 3 | 0/3 (0 %) | 0/3 (0 %) | N.a. | N.a. | ||
| Group IV | 54 | 54 | 1:1.3 | 38 | 1/54 (1.9 %) | 1/54 (1.9 %) | 1:320* | 0/1 (0 %) |
| OND | 9 | 9 | 1/9 (11.1 %) | 1/9 (11.1 %) | 1:320* | 0/1 (0 %) | ||
| HC | 45 | 45 | 0/45 (0 %) | 0/45 (0 %) | N.a. | N.a. | ||
| Group II–IV | 228 | 222 | 1:1.9 | 38 | 1/228 (0.5 %) | 1/222 (0.5 %) | 1:320* | 0/1 (0 %) |
| Total | 614 | 522 | 1:2.6 | 38 | 96/614 (15.6 %) | 51/522 (9.8 %) | 1:640 | 0/51 (0 %) |
N.a not applicable, ON optic neuritis, mON monophasic ON, rON recurrent ON, MY myelitis, LETM longitudinally extensive transverse myelitis, MS multiple sclerosis, OND other neurological disorders, RRMS relapsing remitting MS, SPMS secondary progressive MS, PPMS primary progressive MS, HC healthy control. aSuspected diagnosis at the time of sample referral. §MOG-IgG-positive samples only. *Single patient